

Łomianki, 31.08.2017r.

Purchaser:

Celon Pharma S.A.

Mokra 41A

05-092 Łomianki / Kielpin

tel.: +48 22 751 59 33

fax: +48 22 751 74 77

KRS: 0000437778

NIP: 118 - 16 - 42 - 061

e-mail: anna.dulinska@celonpharma.com

Bidders involved in the procedure

Notification for the extension of the evaluation period of Request for Quotation (RfQ) no. 5/2017/M/NATCO/Z12/BIOL regarding research work to be subcontracted:

- Appropriate dose range finding study with toxicokinetics (TK) in rodent species, using the intended route of administration,
- In vitro Bacterial Reverse Mutation (AMES) test,
- In vitro hERG Channel Assay,

in the project: Non-amyloid therapy for cognitive disorders as a part of the 3rd edition of the contest of the "Program Badań Stosowanych"

Statement of reasons

This has been necessitated by the complexity of the tendering procedure and the need for explanations and analysis of the bids. The final decision will be communicated on **7.09.2017**. The decision is pursuant to Article 27 of the Request for Quotation (RfQ) no. 5/2017/M/NATCO/Z12/BIOL (8th August, 2017).

Celon Pharma S.A.

HQ Office: Ogrodowa 2A, Kielpin

05-092 Łomianki, Poland

phone: +48 22 751 59 33

fax: +48 22 751 44 58

e-mail: info@celonpharma.com

Registering authority: District Court for the Capital City of Warsaw,

14th Commercial Department of the National Court Register

President of the Management Board: Maciej Wieczorek

National Court Register entry number (KRS): 0000437778

Share capital: 4 500 000 PLN

Tax ID number (NIP) : 118 – 16 – 42 – 061

www.celonpharma.com